Pregabalin pharmacology and its relevance to clinical practice

被引:375
作者
Ben-Menachem, E [1 ]
机构
[1] Univ Gothenburg, Dept Clin Neurosci, Gothenburg, Sweden
关键词
pregabalin; antiepileptic drugs; adjunctive therapy; partial seizures; pharmacology; pharmacokinetics; drug interactions; animal models; alpha-2-delta;
D O I
10.1111/j.0013-9580.2004.455003.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha-2-delta site reduces depolarization-induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is similar to1 h and steady state is achieved within 24-48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t(1/2)) Of 6.3 h, and dose-proportional maximal plasma concentrations and total exposures predict a dose-response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug-drug interactions-an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [41] Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
    DeLeon, A
    Patel, NC
    Crismon, ML
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (05) : 649 - 666
  • [42] Carthami flos: a review of its ethnopharmacology, pharmacology and clinical applications
    Tu, Yanhua
    Xue, Yingru
    Guo, Dandan
    Sun, Lianna
    Guo, Meili
    [J]. REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2015, 25 (05): : 553 - 566
  • [43] Pediatric clinical pharmacology and its implications for antiretroviral drug development
    King, Jennifer
    Acosta, Edward
    [J]. CURRENT OPINION IN HIV AND AIDS, 2008, 3 (03) : 272 - 276
  • [44] Anoectochilus roxburghii: A review of its phytochemistry, pharmacology, and clinical applications
    Ye, Shenyi
    Shao, Qingsong
    Zhang, Ailian
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2017, 209 : 184 - 202
  • [45] Pregabalin Controlled-Release Pharmacokinetics in Healthy Volunteers: Analysis of Four Multiple-Dose Randomized Clinical Pharmacology Studies
    Marci L. Chew
    Christine W. Alvey
    Anna Plotka
    Verne W. Pitman
    Tanja Alebic-Kolbah
    Joseph M. Scavone
    Howard N. Bockbrader
    [J]. Clinical Drug Investigation, 2014, 34 : 627 - 637
  • [46] Pharmacology, toxicology and clinical safety of glycopyrrolate
    Chabicovsky, Monika
    Winkler, Swantje
    Soeberdt, Michael
    Kilic, Ana
    Masur, Clarissa
    Abels, Christoph
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 370 : 154 - 169
  • [47] Clinical pharmacology of cannabidiol in refractory epilepsy
    Schaiquevich, Paula
    Riva, Natalia
    Maldonado, Cecilia
    Vazquez, Marta
    Caceres-Guido, Paulo
    [J]. FARMACIA HOSPITALARIA, 2020, 44 (05) : 222 - 229
  • [48] Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period
    Samardzic, Janko
    Allegaert, Karel
    Wilbaux, Melanie
    Pfister, Marc
    van den Anker, John N.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (04) : 367 - 375
  • [49] Alpinetin: A Review of Its Pharmacology and Pharmacokinetics
    Zhao, Ge
    Tong, Yue
    Luan, Fei
    Zhu, Wenjing
    Zhan, Chenglin
    Qin, Tiantian
    An, Weixiao
    Zeng, Nan
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] The clinical pharmacology of therapeutic monoclonal antibodies
    Roskos, LK
    Davis, CG
    Schwab, GM
    [J]. DRUG DEVELOPMENT RESEARCH, 2004, 61 (03) : 108 - 120